| Literature DB >> 35859883 |
Steffen Brunst1, Julia Schönfeld1, Peter Breunig2, Luisa D Burgers3, Murphy DeMeglio2, Johanna H M Ehrler1, Felix F Lillich1, Lilia Weizel1, Jasmin K Hefendehl2, Robert Fürst3, Ewgenij Proschak1, Kerstin Hiesinger1.
Abstract
Soluble epoxide hydrolase (sEH) is a promising target for a number of inflammation-related diseases. In addition, inhibition of sEH has been shown to reduce neuroinflammation, which plays a critical role in the development of central nervous system (CNS) diseases such as Alzheimer's disease. In this study, we present the rational design of a small fluorescent sEH inhibitor. Starting from the clinical candidate GSK2256294A, we replaced the triazine moiety with the 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) fluorophore. The resulting fluorescent sEH inhibitor displayed excellent potency in an in vitro enzyme activity assay (IC50 < 2 nM). The developed inhibitor is applicable in a NanoBRET-based assay system suitable for studying sEH target engagement in living cells. Furthermore, the inhibitor can be used to visualize sEH in sEH-transfected HEK293 cells and in primary mouse astrocytes by fluorescence microscopy.Entities:
Year: 2022 PMID: 35859883 PMCID: PMC9290038 DOI: 10.1021/acsmedchemlett.2c00073
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.632